Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
110 participants
INTERVENTIONAL
2019-01-01
2021-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are;
* is ATX a reliable tumor marker for breast cancer patients in diagnosis
* can ATX differentiate cancer patients from non-cancer ones
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autotaxin (ATX) as a Marker for Breast Cancer
NCT04328194
International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study
NCT03078036
Sentinel Lymph Node Biopsy to Assess Axillary Lymph Nodes in Women With Stage I or Stage II Breast Cancer
NCT00005821
Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants
NCT05054010
Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer
NCT00003854
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast Cancer Patients
Group of patients with verified breast cancer diagnosis
measurement of serum autotaxin serum level
autotaxin expression
Non-Cancer patients
Group of healthy patients with no verified any type of cancer.
measurement of serum autotaxin serum level
autotaxin expression
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
measurement of serum autotaxin serum level
autotaxin expression
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Diskapi Yildirim Beyazit Education and Research Hospital
OTHER_GOV
Ankara Etlik City Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gaye Seker
Assistant Professor of Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Duray Seker, Professor
Role: STUDY_CHAIR
Ankara Etlik City Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara Etlik City Hospital
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287.
Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog. 2009 Sep;48(9):801-9. doi: 10.1002/mc.20524.
Brindley DN, Tang X, Meng G, Benesch MGK. Role of Adipose Tissue-Derived Autotaxin, Lysophosphatidate Signaling, and Inflammation in the Progression and Treatment of Breast Cancer. Int J Mol Sci. 2020 Aug 18;21(16):5938. doi: 10.3390/ijms21165938.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
autotaxin1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.